{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:42:16Z","timestamp":1792575736328,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["209265\/Z\/17\/Z"],"award-info":[{"award-number":["209265\/Z\/17\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Mortality rates for African children with severe malaria remain high. Sevuparin, a heparin-like compound, as an adjunctive treatment, may improve outcomes due to its effects on\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    -infected erythrocytes. A Phase I dose-finding trial in Kenyan and Zambian children with severe malaria aimed to identify the maximum tolerated dose (MTD) of sevuparin, given as three infusions (at 0, 8 and 16\u2009h post-enrolment) using the continual reassessment method (ISRCTN32271864). The primary endpoint was dose limiting toxicity (DLT) defined as Activated Partial Thromboplastin Time (APTT)\u2009&gt;\u200995\u2009seconds (2.5x\u00a0upper limit of normal) across 1.5-6\u2009mg\/kg doses. Secondary endpoints were lactate clearance, parasite half-life, APTT at 24\u2009h and grade 3-4 serious adverse events. Twenty-three children were enroled; 20 were included in the primary analysis, across 10 cohorts. A data monitoring committee followed model recommendations, leading to dose escalation from 1.5\u2009mg\/kg through all doses to 6\u2009mg\/kg when 2 DLTs occurred. During de-escalation, DLTs occurred at 5\u2009mg\/kg and 4\u2009mg\/kg. The final dose was therefore 3\u2009mg\/kg. There was 1 death (1\/23 (4.3%)), 1 readmission and 1 grade 3 non-DLT adverse event: all judged unrelated to sevuparin. MTD of 3\u2009mg\/kg sevuparin in each of three infusions at 0, 8 and 16\u2009h was identified for future investigation.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-78536-3","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:02:54Z","timestamp":1792573374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sevuparin in children with severe malaria: a phase I safety and dose-finding trial"],"prefix":"10.1038","volume":"17","author":[{"given":"Mike","family":"Chaponda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Gwasupika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4408-4336","authenticated-orcid":false,"given":"Roisin","family":"Connon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Tshilab Kabwit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Miti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5040-4359","authenticated-orcid":false,"given":"Nchafatso","family":"Obonyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana M.","family":"Gibb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas N.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P. J.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5190-2395","authenticated-orcid":false,"given":"Arjen M.","family":"Dondorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Sarah","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2928-3580","authenticated-orcid":false,"given":"Elizabeth C.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0007-0645","authenticated-orcid":false,"given":"Kathryn","family":"Maitland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"78536_CR1","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1016\/S0140-6736(17)33080-5","volume":"390","author":"P Alonso","year":"2017","unstructured":"Alonso, P. & Noor, A. M. The global fight against malaria is at crossroads. Lancet 390, 2532\u20132534 (2017).","journal-title":"Lancet"},{"key":"78536_CR2","unstructured":"WHO. World Malaria Report 2024. (World Health Organization, 2024)."},{"key":"78536_CR3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1093\/cid\/ciz844","volume":"71","author":"S Akech","year":"2020","unstructured":"Akech, S. et al. The clinical profile of severe pediatric malaria in an area targeted for routine RTS,S\/AS01 malaria vaccination in Western Kenya. Clin. Infect. Dis. 71, 372\u2013380 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"78536_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-019-1359-9","volume":"17","author":"P Njuguna","year":"2019","unstructured":"Njuguna, P. et al. Observational study: 27 years of severe malaria surveillance in Kilifi, Kenya. BMC Med. 17, 124 (2019).","journal-title":"BMC Med."},{"key":"78536_CR5","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/S0140-6736(10)61924-1","volume":"376","author":"AM Dondorp","year":"2010","unstructured":"Dondorp, A. M. et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 376, 1647\u20131657 (2010).","journal-title":"Lancet"},{"key":"78536_CR6","doi-asserted-by":"crossref","unstructured":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31\u201345 (2015).","DOI":"10.1016\/S0140-6736(15)60721-8"},{"key":"78536_CR7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","volume":"403","author":"MS Datoo","year":"2024","unstructured":"Datoo, M. S. et al. Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.  Lancet 403, 533\u2013544 (2024).","journal-title":"Lancet"},{"key":"78536_CR8","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMp1613528","volume":"375","author":"K Maitland","year":"2016","unstructured":"Maitland, K. Severe Malaria in African children - the need for continuing investment. N. Engl. J. Med 375, 2416\u20132417 (2016).","journal-title":"N. Engl. J. Med"},{"key":"78536_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-014-0263-6","volume":"13","author":"K Maitland","year":"2015","unstructured":"Maitland, K. Management of severe paediatric malaria in resource-limited settings. BMC Med 13, 42 (2015).","journal-title":"BMC Med"},{"key":"78536_CR10","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1056\/NEJMoa1101549","volume":"364","author":"K Maitland","year":"2011","unstructured":"Maitland, K. et al. Mortality after fluid bolus in African children with severe infection. N. Engl. J. Med 364, 2483\u20132495 (2011).","journal-title":"N. Engl. J. Med"},{"key":"78536_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(12)60034-8","volume":"379","author":"CJL Murray","year":"2012","unstructured":"Murray, C. J. L. et al. Global malaria mortality between 1980 and 2010: a systematic analysis.  Lancet 379, 413\u2013431 (2012).","journal-title":"Lancet"},{"key":"78536_CR12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/infdis\/jit116","volume":"208","author":"NJ White","year":"2013","unstructured":"White, N. J., Turner, G. D., Day, N. P. & Dondorp, A. M. Lethal malaria: Marchiafava and Bignami were right. J. Infect. Dis. 208, 192\u2013198 (2013).","journal-title":"J. Infect. Dis."},{"key":"78536_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0031182019001288","volume":"147","author":"F McQuaid","year":"2020","unstructured":"McQuaid, F. & Rowe, J. A. Rosetting revisited: a critical look at the evidence for host erythrocyte receptors in Plasmodium falciparum rosetting. Parasitology 147, 1\u201311 (2020).","journal-title":"Parasitology"},{"key":"78536_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nm986","volume":"10","author":"TE Taylor","year":"2004","unstructured":"Taylor, T. E. et al. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nat. Med. 10, 143\u2013145 (2004).","journal-title":"Nat. Med."},{"key":"78536_CR15","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/infdis\/jir812","volume":"205","author":"MJ Ponsford","year":"2012","unstructured":"Ponsford, M. J. et al. Sequestration and microvascular congestion are associated with coma in human cerebral malaria. J. Infect. Dis. 205, 663\u2013671 (2012).","journal-title":"J. Infect. Dis."},{"key":"78536_CR16","doi-asserted-by":"publisher","first-page":"e0118898","DOI":"10.1371\/journal.pone.0118898","volume":"10","author":"D Angeletti","year":"2015","unstructured":"Angeletti, D., Sandalova, T., Wahlgren, M. & Achour, A. Binding of subdomains 1\/2 of PfEMP1-DBL1alpha to heparan sulfate or heparin mediates Plasmodium falciparum rosetting. PLoS One 10, e0118898 (2015).","journal-title":"PLoS One"},{"key":"78536_CR17","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1182\/blood.V95.11.3594","volume":"95","author":"A Barragan","year":"2000","unstructured":"Barragan, A. et al. The Duffy-binding-like domain 1 of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is a heparan sulfate ligand that requires 12 mers for binding. Blood 95, 3594\u20133599 (2000).","journal-title":"Blood"},{"key":"78536_CR18","doi-asserted-by":"publisher","first-page":"00709","DOI":"10.1128\/aac","volume":"61","author":"MJ Boyle","year":"2017","unstructured":"Boyle, M. J. et al. Identification of heparin modifications and polysaccharide inhibitors of plasmodium falciparum merozoite invasion that have potential for novel drug development. Antimicrob. Agents Chemother. 61, 00709\u201300717 https:\/\/doi.org\/10.1128\/aac (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"78536_CR19","first-page":"489","volume":"16","author":"M Munir","year":"1976","unstructured":"Munir, M., Husada, T., Rampengan, T. H., Mustadjab, I. & Wulur, F. H. Heparin in the treatment of cerebral malaria (a preliminary report). Paediatr. Indones. 16, 489\u2013495 (1976).","journal-title":"Paediatr. Indones."},{"key":"78536_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.14238\/pi20.1-2.1980.47-50","volume":"20","author":"M Munir","year":"1980","unstructured":"Munir, M., Tjandra, H., Rampengan, T. H., Mustadjab, I. & Wulur, F. H. Heparin in the treatment of cerebral malaria. Paediatr. Indones. 20, 47\u201350 (1980).","journal-title":"Paediatr. Indones."},{"key":"78536_CR21","doi-asserted-by":"publisher","first-page":"608","DOI":"10.4269\/ajtmh.1991.45.608","volume":"45","author":"CJ Hemmer","year":"1991","unstructured":"Hemmer, C. J., Kern, P., Holst, F. G., Nawroth, P. P. & Dietrich, M. Neither heparin nor acetylsalicylic acid influence the clinical course in human Plasmodium falciparum malaria: a prospective randomized study. Am. J. Trop. Med Hyg. 45, 608\u2013612 (1991).","journal-title":"Am. J. Trop. Med Hyg."},{"key":"78536_CR22","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/S0140-6736(72)92716-X","volume":"300","author":"H Reid","year":"1972","unstructured":"Reid, H. & Sucharit, P. Ancrod, heparin, and\u2208-aminocaproic acid in simian knowlesi malaria.  Lancet 300, 1110\u20131112 (1972).","journal-title":"Lancet"},{"key":"78536_CR23","doi-asserted-by":"publisher","first-page":"e0172718","DOI":"10.1371\/journal.pone.0172718","volume":"12","author":"S Saiwaew","year":"2017","unstructured":"Saiwaew, S. et al. Effects of sevuparin on rosette formation and cytoadherence of Plasmodium falciparum infected erythrocytes. PLoS One 12, e0172718 (2017).","journal-title":"PLoS One"},{"key":"78536_CR24","unstructured":"Modus Therapeutics A. B., Low anticoagulant heparins (WO2013\/095276) (2013)."},{"key":"78536_CR25","doi-asserted-by":"crossref","unstructured":"Severe malaria. Trop. Med. Int. Health 19 Suppl 1, 7-131 (2014).","DOI":"10.1111\/tmi.12313_2"},{"key":"78536_CR26","doi-asserted-by":"publisher","first-page":"e0188754","DOI":"10.1371\/journal.pone.0188754","volume":"12","author":"AM Leitgeb","year":"2017","unstructured":"Leitgeb, A. M. et al. Inhibition of merozoite invasion and transient de-sequestration by sevuparin in humans with Plasmodium falciparum malaria. PLoS One 12, e0188754 (2017).","journal-title":"PLoS One"},{"key":"78536_CR27","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S2352-3026(21)00053-3","volume":"8","author":"BJ Biemond","year":"2021","unstructured":"Biemond, B. J. et al. Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.  Lancet Haematol. 8, e334\u2013e343 (2021).","journal-title":"Lancet Haematol."},{"key":"78536_CR28","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1093\/infdis\/jis400","volume":"206","author":"J Hanson","year":"2012","unstructured":"Hanson, J. et al. Relative contributions of macrovascular and microvascular dysfunction to disease severity in falciparum malaria. J. Infect. Dis. 206, 571\u2013579 (2012).","journal-title":"J. Infect. Dis."},{"key":"78536_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0407-3","volume":"13","author":"EC George","year":"2015","unstructured":"George, E. C. et al. Predicting mortality in sick African children: the FEAST Paediatric Emergency Triage (PET) Score. BMC Med 13, 174 (2015).","journal-title":"BMC Med"},{"key":"78536_CR30","doi-asserted-by":"publisher","first-page":"987","DOI":"10.4269\/ajtmh.2009.09-0406","volume":"81","author":"OK Doumbo","year":"2009","unstructured":"Doumbo, O. K. et al. High levels of Plasmodium falciparum rosetting in all clinical forms of severe malaria in African children. Am. J. Trop. Med. Hyg. 81, 987\u2013993 (2009).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"78536_CR31","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809164","volume":"11","author":"J Storm","year":"2019","unstructured":"Storm, J. et al. Cerebral malaria is associated with differential cytoadherence to brain endothelial cells. EMBO Mol. Med 11, e9164 (2019).","journal-title":"EMBO Mol. Med"},{"key":"78536_CR32","first-page":"785","volume":"784","author":"S Shah","year":"2022","unstructured":"Shah, S. Common terminology criteria for adverse events. Natl. Cancer Inst. USA 784, 785 (2022).","journal-title":"Natl. Cancer Inst. USA"},{"key":"78536_CR33","doi-asserted-by":"publisher","first-page":"484","DOI":"10.12688\/wellcomeopenres.20111.1","volume":"8","author":"K Maitland","year":"2023","unstructured":"Maitland, K. et al. SEVUparin as a potential adjunctive treatment in children with severe malaria: a phase I trial safety and dose finding trial (SEVUSMAART). Wellcome Open Res 8, 484 (2023).","journal-title":"Wellcome Open Res"},{"key":"78536_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-12-90","volume":"12","author":"K Maitland","year":"2011","unstructured":"Maitland, K., Molyneux, S., Boga, M., Kiguli, S. & Lang, T. Use of deferred consent for severely ill children in a multi-centre phase III trial. Trials 12, 90 (2011).","journal-title":"Trials"},{"key":"78536_CR35","doi-asserted-by":"publisher","unstructured":"WHO guidelines for malaria, 10 September 2026. (World Health Organization, Geneva, 2026). https:\/\/doi.org\/10.2471\/B09879.","DOI":"10.2471\/B09879"},{"key":"78536_CR36","unstructured":"(IDDO), I.D.D.O. Parasite Clearance Estimator (PCE, 2011)."},{"key":"78536_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v054.i13","volume":"54","author":"M Sweeting","year":"2013","unstructured":"Sweeting, M., Mander, A. & Sabin, T. Bayesian continual reassessment method designs for phase I dose-finding trials. J. Stat. Softw. 54, 1\u201326 (2013).","journal-title":"J. Stat. Softw."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-78536-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-78536-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-78536-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:02:56Z","timestamp":1792573376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-78536-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["78536"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-78536-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"11 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10693"}}